Image of Javier Martin

Javier Martin's Email & Phone Number

Chief Medical Officer at Arrowhead Pharmaceuticals

Javier Martin's Email Addresses

j****[email protected] Personal Email

Javier Martin's Phone Numbers

(**) *** *** 193 Phone number

Javier Martin's Work Experience

Arrowhead Pharmaceuticals

Chief Medical Officer

November 2019 to Present

CIRM (California Institute for Regenerative Medicine)

Advisor in Clinical Development

November 2011 to November 2019

Ultragenyx Pharmaceutical Inc.

SrVP Clinical Development

December 2013 to November 2019

Show more

Javier Martin's Education

Universidad de Buenos Aires / UBA

January 1984 to January 1989

Javier Martin's Professional Skills Radar Chart

Based on our findings, Javier Martin is ...

Harmonious
Persuasive
Structured

What's on Javier Martin's mind?

Based on our findings, Javier Martin is ...

52% Left Brained
48% Right Brained

Javier Martin's Estimated Salary Range

About Javier Martin's Current Company

Arrowhead Pharmaceuticals

Frequently Asked Questions about Javier Martin

What company does Javier Martin work for?

Javier Martin works for Arrowhead Pharmaceuticals


What is Javier Martin's role at Arrowhead Pharmaceuticals?

Javier Martin is Chief Medical Officer


What is Javier Martin's personal email address?

Javier Martin's personal email address is j****[email protected]


What is Javier Martin's business email address?

Javier Martin's business email address is [email protected]***.***


What is Javier Martin's Phone Number?

Javier Martin's phone (**) *** *** 193


What industry does Javier Martin work in?

Javier Martin works in the Biotechnology industry.


About Javier Martin

💼 Past Experience

Javier San Martin is currently a Chief Medical Officer at Arrowhead Pharmaceuticals in Pasadena, CA. . SrVP Clinical Development at Ultragenyx Pharmaceutical Inc. from December 2013 to November 2019 (6 years) in Novato, California,. . Advisor in Clinical Development at CIRM (California Institute for Regenerative Medicine) from November 2011 to November 2019 (8 years 1 month) in San Francisco, CA. Advisor and reviewer of applications for stem cell clinical research projects. SVP Clinical Development at Alder Biopharmaceuticals from January 2012 to May 2013 (1 year 5 months) in Greater Seattle Area. Provided strategic and technical advise to small and mid-size biotechnology firms on translation science, drug development, regulatory and commercialization strategies whether as a part of-time Chief Medical Officer or as a consultant supporting a drug development team. Developed and executed clinical programs, including selection and contract negotiations with CROs, SMOs, Networks and Academic Medical Centers.Licensing and strategy advisory services to Latin American biopharmaceutical companies. Exec Director Drug Development at Amgen from March 2010 to September 2011 (1 year 7 months) in Thousand Oaks CA. Developed a paradigm shift in osteoporosis and fracture healing clinical practice with the potential to significantly reduce treatment cost. Developed end of phase 2 briefing document, which was successfully discussed with regulatory authorities.Identified a target patient population within a prevalent disease for whom a new biologic therapeutic will provide a clinical benefit over generic standard of care. Developed a phase 3 clinical program to enable regulatory success by demonstrating a unique clinical benefit that will support a robust comparative effectiveness data package. Executive Director, Global Development Leader Denosumab at Amgen from March 2006 to March 2010 (4 years 1 month) in Thousand Oaks. Led Global Development team responsible for ~$600M development program with over 30 clinical trials and more than 14,000 patients. Responsibilities included oversight of study operations and CRO partners, global regulatory submissions, on-time delivery of global license applications, interaction with regulatory agencies, and FDA advisory committee strategy.Led Daiichi-Sankyo Amgen Joint Development Program and advised Daiichi-Sankyo on its clinical program that was successfully executed in Japan. Medical Advisor at Eli Lilly and Company from June 2000 to March 2006 (5 years 10 months) in Indianapolis, Indiana Area. Designed, implemented and reported phase 3B/4 clinical trials on osteoporosis treatment and other indication with PTH and anti-resorptive therapy.Participated in reimbursement dossier preparation and regulatory responses with Australia and Latin American countries, resulting in the dossier preparation.Lectured extensively in the US, Canada, Europe and Latin America.Led and coordinated Medical affairs activities at launch of Forteo and Evista through Latin America and Asia countries. Clinical Research Physician – Endocrine Therapeutic Area at Eli Lilly and Company from June 1998 to June 2000 (2 years 1 month) in Indianapolis, Indiana Area. Designed and implemented a phase 4 raloxifene and HRT study on new breast cancer surrogate, resulting in publication and conference presentations.Led and coordinated Medical affairs activities at launch of Evista throughout Latin America and Asia countries


🎓 Education

EducationJavier San Martin's undergraduate education began at Universidad de Buenos Aires (UBA) in 1984. After four years of j Medicina, he completed his MD in 1989. After completing his PhD at the University of Oxford in 1993, Javier San Martin joined Universidad de Buenos Aires as a researcher.Research and Professional ExperienceJavier San Martin has been a researcher at Universidad de Buenos Aires (UBA) since 1993. He has been conducting research on a range of medical and scientific topics. His research has included studies on cancer and its treatment, heart disease and its treatment, and stroke. Currently, Javier San Martin is the head of the Department of Epidemiology and Prevention at the University of Buenos Aires (UBA). He is also the V.E.P. of the Coordination and Collaboration of Epidemiology and Prevention Units at the University of Buenos Aires (UBA).Major AchievementsJavier San Martin has been involved in many major achievements during his career. He is responsible for the development of new methods for studying heart disease and stroke, as well as for the development of Centers of Excellence for Prevention and Treatment ofHeart Disease and Stroke at the University of Buenos Aires (UBA). Javier San Martin also helped to establish the World Health Organization (WHO) Global Co-ordinating centre for preventative clinical measures for heart disease and stroke.


💡 Technical & Interpersonal Skills

Javier San Martin's Professional Experience:Chief Medical Officer at Arrowhead PharmaceuticalsSrVP Clinical Development at Ultragenyx Pharmaceutical Inc. from December 2013 to November 2019 (6 years) in Novato, California Advisor in Clinical Development at CIRM (California Institute for Regenerative Medicine) from November 2011 to November 2019 (8 years 1 month) in San Francisco, CA Advisor and reviewer of applications for stem cell clinical research projectsSVP Clinical Development at Alder Biopharmaceuticals from January 2012 to May 2013 (1 year 5 months) in Greater Seattle AreaProvided strategic and technical advice to small and mid-size biotechnology firms on translation science, drug development, regulatory and commercialization strategies whether as a part of a Chief Medical Officer or as a consultant supporting a drug development team.Developed and executed clinical programs, including selection and contract negotiations with CROs, SMOs, Networks and Academic Medical Centers.Licensing and strategy advisory services to Latin American biopharmaceutical companies.Exec Director Drug Development at Amgen from March 2010 to September 2011 (1 year 7 months) in Thousand Oaks CADeveloped a paradigm shift in osteoporosis and fracture healing clinical practice with the potential to significantly reduce treatment cost.Developed end of phase 2 briefing document, which was successfully discussed with regulatory authorities.Identified a target patient population within a prevalent disease for whom a new biologic therapeutic will provide a clinical benefit over generic standard of care.Developed a phase 3 clinical program to enable regulatory success by demonstrating a unique clinical benefit that will support a robust comparative effectiveness data package.Executive Director, Global Development Leader Denosumab at Amgen from March 2006 to March 2010 (4 years 1 month) in Thousand Oaks. Led Global Development team responsible for ~$600M development program with over 30 clinical trials and more than 14,000 patients.Responsibilities included oversight of study operations and CRO partners, global regulatory submissions, on-time delivery of global license applications, interaction with regulatory agencies, and FDA advisory committee strategy.Led Daiichi-Sankyo Amgen Joint Development Program and advised Daiichi-Sankyo on its clinical program that was successfully executed in JapanMedical Advisor at Eli Lilly and Company from June 2000 to March 2006 (5 years 10 months) in Indianapolis, Indiana AreaDesignated, designed, and reported phase 3B/4 clinical trials on osteoporosis treatment and other indication with PTH and anti-resorptive therapy.Participated in reimbursement dossier preparation and Regulatory responses with Australia and Latin American countries, resulting in the dossier preparation.Lectured extensively in the US, Canada, Europe and Latin America.Led and coordinated Medical affairs activities at launch of Forteo and Evista through Latin America and Asia countries.clinical Research Physician – Endocrine Therapeutic Area at Eli Lilly and Company from June 1998 to June 2000 (2 years 1 year) in Indianapolis, Indiana AreaLeeded and coordinated Medical affairs activities at launch


Javier Martin’s Personal Email Address, Business Email, and Phone Number

are curated by ContactOut on this page.

10x your recruitment & sales conversations

Contact over 250M professionals instantly by email or phone. Reveal personal & work email addresses, as well as phone numbers accurately with our ContactOut Chrome extension.
Sign up for free

In a nutshell

Javier Martin's Personality Type

Extraversion (E), Sensing (S), Feeling (F), Judging (J)

Average Tenure

2 year(s), 0 month(s)

Javier Martin's Willingness to Change Jobs

Unlikely

Likely

Open to opportunity?

There's 97% chance that Javier Martin is seeking for new opportunities

Javier Martin's Social Media Links

/in/javiersanmartinmd
Engage candidates 10x faster

Enjoy unlimited access and discover candidates outside of LinkedIn

Trusted by 400K users from 76% of Fortune 500 companies

Microsoft Nestle PWC JP Morgan Merck Rackspace WarnerMedia Randstad Yelp Google

The most accurate data ever

CCPA Compliant
GDPA Aligned
150M Personal Emails
200M Work Emails
100M Direct Dials
250M Professional Profiles
30M Company Profiles

Find anyone, anywhere
with ContactOut today

Making remote or global hires? Connecting
with key decision-makers? We can help.

  • 40 emails / month
  • 3 phone numbers / month
  • Works on standard LinkedIn only
  • Work emails, personal emails,
    mobile numbers
* 1 user per company limit

No credit card required

Try ContactOut for Free